Bioheng Received Orphan Drug Designation(ODD) from the U.S. FDA for the Treatment of T-ALL
Release Time:
2021-06-21
Source:
Reprint to:
Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).
"CTD401 is the first innovative product based on our next-generation generic CAR-T technology platform. It has excellent efficacy and superior safety in exploratory clinical studies," said Dr. JiangTao Ren, President and Chief Scientific Officer of Bioheng, "Orphan drug accreditation not only reflects the confidence of the international authority FDA on CTD401, but also is an important milestone of Bioheng gradual globalization."
CTD401 is a universal CAR-T (UCAR-T) cell therapy product developed by Bioheng for the treatment of patients with T-ALL. The product is prepared by collecting peripheral blood mononuclear cells (PBMC) from healthy donors, using a virus encoding a CD7 CAR gene for transduction, and using CRISPR/cas9 technology to knock out key genes.
About ODD
The Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects less than 200,000 persons in the US or meets cost recovery provisions of the act. After obtaining the ODD, pharmaceutical companies could receive various incentives for the drug development, including 25% federal tax credit for expenses incurred in conducting clinical research within the United States, Waiver of Prescription Drug User Fee Act (PDUFA) fees for orphan drugs, qualifed to compete for research grants from the Office of Orphan Products Development (OOPD) to support clinical studies for orphan drugs, eligibility to receive regulatory assistance and guidance from the FDA in the design of an overall drug development plan and 7-year marketing exclusivity.
Related News
On April 25, 2024, The New England Journal of Medicine published the latest findings by the team of He Huang, M.D., PhD., and Yongxian Hu, M.D., PhD., from the First Affiliated Hospital, Zhejiang University School of Medicine, titled "Sequential CD7 CAR-T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis"[1]. The study introduces an innovative treatment strategy that combines CD7 CAR-T with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the first time.
Bioheng Received CDE IND Approval for CTA101 UCAR-T
On March 17,2022, China National Drug Administration Drug Review Center ( CDE ) approved first Universal Chemeric Antigen Receptor T (UCAR-T) cell drug ( Acceptance No. : CXSL2101509 ) . CTA101 is independently developed by Nanjing Bioheng Biotech Co., Ltd ( hereinafter referred as ' Bioheng), targeting CD19 and CD22, for the indication of adult recurrent or refractory B-cell acute lymphoblastic leukemia ( r / r B-ALL ).
Bioheng鈥榮 Auto CAR-T Product, CTB001, Received Orphan Drug Designation (ODD) from the U.S. FDA
Recently,聽Bioheng Biotech Co., Ltd ( hereinafter referred to as ' Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation ( ODD ) from the Food and Drug Administration ( FDA ) for the treatment of gastric cancer. Gastric cancer has a high incidence in Asian countries such as China and Japan, and the mortality rate ranks the third in the global mortality rate of malignant tumors, behind lung cancer and colorectal cancer. At present, conventional chemotherapy and surgical resection are mainly applied for the gastric cancer treatment, therefore the treatment drugs and methods are very limited.
Bioheng Received Orphan Drug Designation(ODD) from the U.S. FDA for the Treatment of T-ALL
Nanjing Bioheng Biotech Co., Ltd.聽Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).
Bioheng Raised $80 Million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies
NANJING, China, March 24, 2021 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company聽 dedicated聽on developing novel cellular immunotherapy for cancer, today announced that it had secured聽$80 million聽in Series B Financing. The Series B was co-led by GL Ventures, the venture capital unit of Hillhouse Capital, Decheng Capital and Octagon Capital, with the participation of BlueRun Ventures聽China and Shenzhen Capital Group Company.
NANJING, China, Nov. 10, 2020聽-- Bioheng Biotech Co., Ltd, a clinical-stage biotech company focused on developing novel cellular immunotherapy to treat cancer, today announced an oral presentation at 62th The data will be presented regarding the pre-clinical development, manufacturing, and IIT clinical results of the company鈥檚 lead product, CTA101, a CRISPR-Cas9-engineered off-the-shelf CD19/CD22 dual-targeted CAR T cell product, in patients with relapsed / refractory B-cell acute Lymphoblastic Leukemia.
Contact Us